US Patent

US9504699 — Delayed-release glucocorticoid treatment of rheumatoid disease

Method of Use · Assigned to HZNP Ltd · Expires 2027-08-03 · 1y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a delayed-release dosage form of a glucocorticoid for treating rheumatic disease and/or osteoarthritis.

USPTO Abstract

The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof.

Drugs covered by this patent

Deltasone (prednisone) · Generic (originally Schering)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1362`	—	Deltasone
`U-1362`	—	Deltasone
`U-1362`	—	Deltasone

Patent Metadata

Patent number: US9504699
Jurisdiction: US
Classification: Method of Use
Expires: 2027-08-03
Drug substance claim: No
Drug product claim: No
Assignee: HZNP Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.